Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer

ABSTRACT: The estrogen receptor alpha (ERa) drives the growth of two-thirds of all breast cancers. Endocrine therapy impinges on estrogen-induced ERa activation to block tumor growth. However, half of ERa-positive breast cancers are tolerant or acquire endocrine therapy resistance. Here we demonstrate that breast cancer cells undergo genome-wide reprogramming of their chromatin landscape, defined by epigenomic maps and chromatin openness, as they acquire resistance to endocrine therapy. This reveals a role for the Notch pathway while excluding classical ERa signaling. In agreement, blocking Notch signaling, using gamma-secretase inhibitors, or targeting its downstream gene PBX1 abrogates growth of endocrine therapy-resistant breast cancer cells. Moreover Notch signaling through PBX1 directs a transc

ORGANISM(S): Homo sapiens

SUBMITTER: xiaoyang zhang 

PROVIDER: E-GEOD-37323 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress